Inhibition of ERK1/2 and Activation of LXR Synergistically Reduce Atherosclerotic Lesions in ApoE-Deficient Mice
- 1 April 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 35 (4), 948-959
- https://doi.org/10.1161/atvbaha.114.305116
Abstract
Objective—: Activation of liver X receptor (LXR) inhibits atherosclerosis but induces hypertriglyceridemia. In vitro, it has been shown that mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor synergizes LXR ligand–induced macrophage ABCA1 expression and cholesterol efflux. In this study, we determined whether MEK1/2 (U0126) and LXR ligand (T0901317) can have a synergistic effect on the reduction of atherosclerosis while eliminating LXR ligand–induced fatty livers and hypertriglyceridemia. We also set out to identify the cellular mechanisms of the actions. Approach and Results—: Wild-type mice were used to determine the effect of U0126 on a high-fat diet or high-fat diet plus T0901317-induced transient dyslipidemia and liver injury. ApoE deficient (apoE −/− ) mice or mice with advanced lesions were used to determine the effect of the combination of T0901317 and U0126 on atherosclerosis and hypertriglyceridemia. We found that U0126 protected animals against T0901317-induced transient or long-term hepatic lipid accumulation, liver injury, and hypertriglyceridemia. Meanwhile, the combination of T0901317 and U0126 inhibited the development of atherosclerosis in a synergistic manner and reduced advanced lesions. Mechanistically, in addition to synergistic induction of macrophage ABCA1 expression, the combination of U0126 and T0901317 maintained arterial wall integrity, inhibited macrophage accumulation in aortas and formation of macrophages/foam cells, and activated reverse cholesterol transport. The inhibition of T0901317-induced lipid accumulation by the combined U0126 might be attributed to inactivation of lipogenesis and activation of lipolysis/fatty acid oxidation pathways. Conclusions—: Our study suggests that the combination of mitogen-activated protein kinase kinase 1/2 inhibitor and LXR ligand can function as a novel therapy to synergistically reduce atherosclerosis while eliminating LXR-induced deleterious effects.Keywords
This publication has 38 references indexed in Scilit:
- Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesionEuropean Heart Journal, 2012
- Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in miceJCI Insight, 2012
- Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXRNature Reviews Molecular Cell Biology, 2012
- The Role of Triglycerides in AtherosclerosisCurrent Cardiology Reports, 2011
- Inhibition of ERK1/2 and Activation of Liver X Receptor Synergistically Induce Macrophage ABCA1 Expression and Cholesterol EffluxOnline Journal of Public Health Informatics, 2010
- A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent CardioprotectionScience, 2008
- PPARα in atherosclerosis and inflammationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Regulation and Mechanisms of ATP-Binding Cassette Transporter A1-Mediated Cellular Cholesterol EffluxArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Increased ABCA1 activity protects against atherosclerosisJCI Insight, 2002
- Epidemiology as a Guide to Clinical DecisionsThe New England Journal of Medicine, 1980